VEGF antisense oligonucleotide (Aventis)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameVEGF antisense oligonucleotide (Aventis)
Drug Alias NameVEGF antisense oligonucleotide (HMR)VEGF antisense oligonucleotide (Hoechst Marion Roussel)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionVascular endothelial growth factor receptor antagonists
TargetsVascular endothelial growth factor receptor
Therapy Area/IndicationsSolid tumoursAngiogenesis disorder
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAventis Pharma
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAventis PharmaHoechst Marion Roussel Ltd
Active IndicationsN/A
Inactive IndicationsSolid tumoursAngiogenesis disorder

Other Information

ATC CodeN/A
Related LinksN/A